Text resize

COUNTRY

ASPREE USA

Phone Icon

612-873-6905

Stay up to date on ASPREE news and events

Resources

ASPREE News

Read the latest project developments and progress, or search ASPREE news and events posts here.

Newsletters

The ASPREE project produces and contributes to a number of publications for a range of audiences.

Biannual ASPREE newsletters are sent to ASPREE-XT study participants, providing an easy to read update on research progress, major developments, publications and findings.

Project updates geared towards the medical community are sent to PCPs and practices with patients in the study.  Researchers involved in the ASPREE project, or with an interest in the research, are updated on developments and outcomes by the Principal Investigators.

Publications

ASPREE project findings are shared with scientists, physicians, doctors and researchers worldwide via publication in quality medical journals.

ASPREE investigators frequently contribute to specialist and broader media articles.

Brochures

Downloable brochures to explain both components of the research: the clinical trial and the follow-up longitudinal study.

Media

Journalists and writers who would like to know more about the ASPREE project or arrange an interview with key investigators on the project, should contact:

Brenda Kirpach, United States Project Manager
PHONE: 612-873-6905
EMAIL: bkirpach@bermancenter.org
MAILING ADDRESS:
The Berman Center
701 Park Avenue., Suite PPC 4.440
Minneapolis, MN 55415

 

 

Contact us

If you are an ASPREE-XT study participant please contact your study site with questions.

ASPREE and ASPREE-XT US Coordinating Center:  Berman Center for Outcomes & Clinical Research
Brenda Kirpach, United States Project Manager
PHONE: 612-873-6905
EMAIL: bkirpach@bermancenter.org
MAILING ADDRESS: The Berman Center
701 Park Avenue., Suite PPC 4.440
Minneapolis, MN 55415

 

Page updated: July 20, 2021

LATEST NEWS

Update: ASPREE-XT study visits and COVID-19
Update: ASPREE-XT study visits and COVID-19

About ASPREE-XT study activity during COVID-19 in the United States. In light of public health recommendations to help slow the spread of Coronavirus (COVID-19) in the community, ASPREE-XT is conducting both face-to-face visits and phone calls,

Aspirin and cognitive decline
Aspirin and cognitive decline

Researchers at Monash University and the Berman Center for Outcomes and Clinical Research report that aspirin does not reduce the risk of Alzheimer’s disease, mild cognitive impairment, or cognitive decline in older adults.

Low-dose aspirin and depression
Low-dose aspirin and depression

Daily low-dose aspirin does not prevent depression in healthy older adults, reports the ASPREE-D (depression) sub-study, the first detailed investigation of its kind.

News resources and media